Table 4.

MSCs-secreted chemokines/biomolecules and their impacts on the hematologic malignancies

Kind of chemokine/biomolecule	Target	Results	References
CXCL12	AML cells	Dampening effect on MSC-mediated resistance to FLT3 inhibition	[95]
CXCL12	CML cells	↓Imatinib-induced cell death	[76]
CXCL12	LSCs of CML	Maintain quiescent of LSCs and TKI-resistant	[83]
Periostin	B-ALL cells	↑B-ALL cell-derived CCL2, ↑ leukemia burden	[88]
Lumican	LSCs of Nalm-6 cell line	Downregulation of anti-apoptotic, resistance to chemotherapy	[89]
CCL3, CCL4, matrix metalloproteinases (MMP)-13, IL-1, IL-3, IL-6, and IL-17	MM cells	Differentiation to osteoclast, bone destruction in MM	[72]
VCAM-1, SDF1, Wnt	AML cells	Residual disease maintenance, drug resistance and disease relapse	[85, 86]
Axl	AML cells	Prognostic factor and therapeutic target	[87]
SDF-1α/CXCR4	CLL cells	Intercellular trafficking of CLL cells	[94]
CXCR4/CXCL12	CML cells	↓Caspase-3 activation, Bcl-XL expression modulation after treatment with imatinib	[93]